Diabetes Professional Care Charity of the year, X-PERT Health, has appointed digital healthcare agency, Pulse, to transform their ground-breaking diabetes education programme onto a digital platform. The new platform, which will be accessible via an app or website, will enable X-PERT Health to scale up its current group based programme, allowing hundreds of thousands more patients to develop the knowledge, understanding and confidence to make lifestyle changes to prevent or manage Type 2 diabetes, further strengthening X-PERT Health's'educate not medicate' philosophy. The educational content will be interactive and engaging, including animated videos, games and quizzes to support discovery learning in a fun and easy-to-use way. The digital programme will also include features such as real-time tracking for diet, physical activity, health results, medication requirement and mood and sleep – helping users to manage and improve their lifestyle and health. This information can then be shared with the users' healthcare professional as part of their regular check-up.
LOS ANGELES--(BUSINESS WIRE)--Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, announced today that the Medical Retina Center and the Diabetic Retinopathy Telescreening Program of the University Eye Clinic of Genoa DINOGMI IRCCS Ospedale Policlinico San Martino, Italy has successfully expanded their diabetic retinopathy (DR) screening program by leveraging the EyeArt AI Eye Screening System. On January 17, 2020, Dr. Donatella Musetti of the Medical Retina Center at the University Eye Clinic of Genoa presented strong EyeArt results on first 712 patients at the Macula in Liguria 2020 Conference. The University Eye Clinic of Genoa is directed by Professor C.E. Traverso and is one of Italy's major cultural and scientific institutions in the Mediterranean and Northwestern Region. "Our Institution is a regional organisation committed to investing in innovation for active and healthy ageing and supporting the transfer and scaling-up of that innovation across Europe," said Massimo Nicolò, MD PhD, associate professor at the University Eye Clinic of Genoa who leads the Medical Retina Center and the Program for Diabetic Retinopathy Telescreening. "For this reason, we are recognized as Reference Site by the European Innovation Program on Active and Healthy Ageing (EIP-AHA) sponsored by the European Commission."
Current methods to measure glucose requires needles and repeated fingerpricks over the day. Fingerpricks can often be painful, deterring patient compliance. A new technology for detecting low glucose levels via ECG using a non-invasive wearable sensor, which with the latest Artificial Intelligence can detect hypoglycaemic events from raw ECG signals has been made by researchers from the University of Warwick. Currently Continuous Glucose Monitors (CGM) are available by the NHS for hypoglycaemia detection (sugar levels into blood or derma). They measure glucose in interstitial fluid using an invasive sensor with a little needle, which sends alarms and data to a display device.
Medtronic's mission is to alleviate pain, restore health, and extend life through the application of biomedical engineering, explains Elaine Gee, PhD, Senior Principal Algorithm Engineer specializing in Artificial Intelligence at Medtronic. It's a mission Gee is well equipped for. With over 15 years' experience in modeling, bioinformatics, and engineering, she drives machine learning algorithm development and analytics to support next-generation medical devices for diabetes management. On behalf of AI Trends, Ben Lakin, from Cambridge Innovation Institute, sat down with Gee to discuss her most recent focus: algorithm development related to glucose sensing to improve the accuracy and performance of continuous glucose monitoring devices, also known as CGMs. Editor's Note: Gee will be giving a featured presentation on Advancing Continuous Glucose Monitoring Sensor Development with Machine Learning at Sensors Summit in San Diego, December 10-12.
Sign in to report inappropriate content. A new technique developed by researchers at the University of Warwick uses the latest findings of Artificial Intelligence to detect hypoglycaemic events from raw ECG signals, via wearable sensors. The technology works with an 82% reliability, and could replace the need for invasive finger-prick testing with a needle, which could be particularly useful for paediatric age patients.
You are free to share this article under the Attribution 4.0 International license. A new technology for detecting low glucose levels uses artificial intelligence to detect hypoglycemic events with ECG signals from wearable sensors, researchers report. Tracking sugar in the blood is crucial for both healthy individuals and diabetic patients, but current methods to measure glucose require needles and repeated finger pricks throughout the day. Finger pricks can often be painful, deterring patient compliance. Currently Continuous Glucose Monitors (CGM) for hypoglycemia detection measure glucose in interstitial fluid using an invasive sensor with a little needle, which sends alarms and data to a display device.
Current methods to measure glucose requires needles and repeated fingerpicks over the day. Fingerpicks can often be painful, deterring patient compliance. A new technology for detecting low glucose levels via ECG using a non-invasive wearable sensor, which with the latest Artificial Intelligence can detect hypoglycaemic events from raw ECG signals has been made by researchers from the University of Warwick. Currently Continuous Glucose Monitors (CGM) are available by the NHS for hypoglycaemia detection (sugar levels into blood or derma). They measure glucose in interstitial fluid using an invasive sensor with a little needle, which sends alarms and data to a display device.
While technologies that impede, rather than enhance care, have made the healthcare industry somewhat skeptical of innovation, a shift toward patient-centric care is changing the game. Healthtech innovations in 2019 are helping to transform the business of care, creating efficiencies, cutting costs, and providing better outcomes. How these new technologies mesh with the clinical skill set of a medical provider is still being determined. Providers who embrace tools now available will help to determine how healthcare delivery looks in 2020 and well beyond. Here's what you need to know: If you aren't offering your patients virtual visits, it's likely they'll find someone who is Virtual visits, often conducted via a smartphone or personal computer, offer convenient access to care, saving patients the time and expense of traveling to an appointment and providing care to those who have limited access to it.
In a move that could help win over some skeptics about the value and efficacy of AI in clinical care, The American Diabetes Association, in its new set of clinical standards, recognizes the use of autonomous artificial intelligence for the screening of some medical conditions. WHY IT MATTERS The ADA's new 2020 Standards of Medical Care in Diabetes includes language noting that "AI systems that detect more than mild diabetic retinopathy and diabetic macular edema authorized for use by the FDA represent an alternative to traditional screening approaches." The clinical standards – published earlier this month in the peer-reviewed journal Diabetes Care – represent a new source for evidence-based best practices, consulted by hospitals and health systems, physicians, insurers and quality organizations. While acknowledging that autonomous AI can be an alternative to traditional screening, however, the ADA specifies that it feels the "benefits and optimal utilization of this type of screening have yet to be fully determined." In addition, it cautions that "artificial intelligence systems should not be used for patients with known retinopathy, prior retinopathy treatment, or symptoms of vision impairment."
The nation's leading association that fights against diabetes released a new set of clinical standards that for the first time include the use of autonomous artificial intelligence (AI). The American Diabetes Association (ADA)'s 2020 Standards of Medical Care in Diabetes states that, "AI systems that detect more than mild diabetic retinopathy and diabetic macular edema authorized for use by the FDA represent an alternative to traditional screening approaches." To date, IDx-DR is the first and only FDA-authorized autonomous AI diagnostic system for the detection of diabetic retinopathy and macular edema. It is currently in use at a number of large health systems that each serve tens of thousands of people with diabetes and have struggled to implement diabetic retinopathy eye exams at scale for their large diabetes population. "The ADA's inclusion of our technology in its Standards of Care marks a significant move toward mainstream adoption of autonomous AI in clinical care," said Michael Abramoff, MD, PhD, Founder and Executive Chairman at IDx. "Our early customers are visionary leaders who foresaw that autonomous AI would one day become a standard of care for diabetic retinopathy screening, and taking that leap is paying off for them. Already, health systems that are using IDx-DR have experienced significant improvements in accessibility, efficiency and compliance rates, unleashing massive potential for cost savings and improved patient outcomes."